
Buy Cartalax Research Peptide
Supplied as a lyophilised powder and independently verified to ≥98% purity by HPLC and MS-UPLC analysis. A batch-specific Certificate of Analysis is included with every order.

Buy Cartalax Research Peptide
Supplied as a lyophilised powder and independently verified to ≥98% purity by HPLC and MS-UPLC analysis. A batch-specific Certificate of Analysis is included with every order.
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Included
Every batch
Ships Next Day
Order before midnight. Dispatched tomorrow with cold-chain packaging
HPLC Verified
≥98% purity
Lyophilised
Powder format
Express Shipping
Cold-chain included
COA Included
Every batch
Ships Next Day
Order before midnight. Dispatched tomorrow with cold-chain packaging
Cartalax, also known by its tripeptide designation AED (Ala-Glu-Asp) and the developmental code T-31, is a synthetic tripeptide bioregulator with the molecular formula C12H19N3O8 and an approximate molecular weight of 333.3 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology, Cartalax was designed based on peptide fractions associated with cartilaginous tissue. Its three-amino acid sequence, Ala-Glu-Asp, shares the AED core motif found in the longer tetrapeptide bioregulators Epithalon (AEDG), Cortagen (AEDP), Cardiogen (AEDR), and Bronchogen (AEDL), representing the minimal tripeptide unit within this structural series. Produced via solid-phase peptide synthesis, Cartalax is associated with chondrocyte gene expression and cartilage matrix signalling pathways.
Cartalax is a tripeptide bioregulator within the Khavinson framework. In mesenchymal stem cell preparations, the tripeptide modulated the expression of genes governing chondrogenic differentiation and cellular metabolic activity, including upregulation of IGF1 and NFκB and effects on TNKS2 within Wnt-associated signalling relevant to cartilage formation [1]. In a parallel in vitro model of mesenchymal stem cell ageing in culture, AED was reported to increase IGF1 gene expression approximately 3.5- to 5.6-fold alongside modulation of FOXO1, TERT, TNKS2 and NFκB, the expression of which otherwise declined with culture ageing [2]. At the whole-animal level, in aged rats, AED administration was associated with altered renal morphofunctional [3], making Cartalax a reference compound in preclinical connective-tissue and cellular-ageing research examining chondrogenic differentiation, regulation of IGF1 and associated gene expression, and morphofunctional changes in aged tissue.
Cartalax is manufactured in a cGMP compliant, ISO9001 certified laboratory to a guaranteed purity of 98% or above. Every batch is independently tested using HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.
Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.
References
Editorial Team

Dr. Martina Rossi, PhD
Scientific Contributor and Reviewer
Reviewed and approved 14 June 2026
What Researchers Say
Sign in to leave a reviewNo reviews yet. Be the first to share your research experience.
Frequently Asked Questions
Select Size
Buy 5+ vials to unlock discounts
Quality Guaranteed
Every batch is HPLC-tested to ≥99% purity. Certificate of Analysis and MSDS available with every order.
